Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2016 (2016), Article ID 7984576, 6 pages
http://dx.doi.org/10.1155/2016/7984576
Clinical Study

Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes

1Department of Ophthalmology, Federal University of São Paulo, São Paulo, SP, Brazil
2Brazilian Institute of Fighting Against Blindness (INBRACE), Assis/Presidente Prudente, SP, Brazil
3Federal University of Goiás, Goiânia, GO, Brazil
4Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA
5Asociados de Macula Vitreo y Retina de Costa Rica, San Jose, Costa Rica
6University of Puerto Rico, San Juan, PR, USA

Received 11 June 2016; Accepted 28 August 2016

Academic Editor: Enrico Peiretti

Copyright © 2016 Eduardo A. Novais et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose. To evaluate the best-corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes. Methods. This multicenter retrospective cohort study included 112 patients with CME secondary to retinal diseases treated pro re nata (PRN) with a 0.7 mg intravitreal dexamethasone implant for 12 months. The BCVA, CRT, adverse events, safety data, and number of implants were recorded. Results. Vitrectomized and nonvitrectomized eyes received means of three implants and one implant, respectively, over 12 months (). The mean BCVA of all patients improved from 0.13 at baseline to 0.33 () 12 months after one (), two (), and three () implants but not four implants (). The mean baseline CRT decreased significantly () from 463 to 254 microns after 12 months with one (), two (), and three () implants but not with four implants (). The anatomic and functional outcomes were not significantly different between vitrectomized and nonvitrectomized eyes. Increased IOP was the most common adverse event (23.2%). Conclusions. Dexamethasone implant administered PRN improved VA and decreased CRT in CME, with possible long-term clinically relevant benefits for treating CME from various etiologies. Vitrectomized eyes needed more implants compared with nonvitrectomized eyes.